Policies
Peer-review process including the type of peer review that is used:
-Authors send their manuscripts to the editor-in-chief at Christophe.Wiart@nottingham.edu.my or asianjpharmcog@gmail.com.
-Once a paper is received the author is contacted and the submission is acknowledged.
-The submitted paper is sent to the Editorial Board and Board of Directors (which encompasses several academic experts in the field and with decades of academic writing experience and with high h-indexes) and a call for at least 2 reviewers is made. The review process is single-blind.
-The submitted paper is sent to a plagiarism officer who generates a report (The Journal reject papers with more than 20% plagiarism)
-The submitted paper is sent to the adjudicator who scores the English language used from 1 to 5.
-When the editor-in-chief has received the reviews, the plagiarism report, and the English language report, conflict of interest indication, and if the paper submitted follows the journal’s policies, he makes a decision: (i) the paper is rejected, (ii) the paper needs major or minor corrections (the author is asked to make the corrections and resend it to the editor-in-chief who then makes a decision), or (iii) the paper is accepted.
-Copyright transfer form is sent to the author
-Paper is published.”
“Journal’s policies on Conflict of Interest, Human, and Animal Rights:
Conflict of Interest
All papers submitted to the editor-in-chief are sent to all members of the Board of Editors and Board of Director of the Asian Society of Pharmacognosy who in turn have the duty to alert the editor-in-chief if the paper is authored by their colleagues, friends, co-researchers, co-authors, family members, or students. If a conflict of interest exists the paper is rejected. Authors are asked to declare in the paper if they have any conflict of interest to declare
Human Rights:
The Asian Journal of Pharmacognosy does not publish papers involving experiments on human subjects that do not follow strictly the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008, which is available at http://www.healthscience.net/resources/declaration-of-helsinki/.
Animal Rights
The Asian Journal of Pharmacognosy does not publish papers involving experiments that do not follow the guidelines of the American Veterinary Medical Association (AVMA) for the Euthanasia of Animals (2020)( https://www.avma.org/sites/default/files/2020-01/2020-Euthanasia-Final-1-17-20.pdf ). Further, authors must provide detailed evidence on whether the institutional and national guide for the care and use of laboratory animals was followed. The materials and methods (experimental procedures) section must indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided. In general, the journal does not encourage the submission of papers involving in vivo works. Any deviation from the above will result in paper rejection.
Informed Consent:
The Asian Journal of Pharmacognosy rejects any paper that does not apply informed consent under research ethics, based on Declaration of Helsinki: Statement of Ethical Principles for Medical Research (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) and ICMJE's Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (http://www.icmje.org/icmje-recommendations.pdf). For publications involving patients for the Asian Journal of Pharmacognosy, patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be published. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication. Patient consent should be written and archived either with the journal, the authors, or both, as dictated by local regulations or laws. Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance, and editors should so note, that such alterations do not distort scientific meaning. When informed consent has been obtained, it should be indicated in the published article.
-Authors send their manuscripts to the editor-in-chief at Christophe.Wiart@nottingham.edu.my or asianjpharmcog@gmail.com.
-Once a paper is received the author is contacted and the submission is acknowledged.
-The submitted paper is sent to the Editorial Board and Board of Directors (which encompasses several academic experts in the field and with decades of academic writing experience and with high h-indexes) and a call for at least 2 reviewers is made. The review process is single-blind.
-The submitted paper is sent to a plagiarism officer who generates a report (The Journal reject papers with more than 20% plagiarism)
-The submitted paper is sent to the adjudicator who scores the English language used from 1 to 5.
-When the editor-in-chief has received the reviews, the plagiarism report, and the English language report, conflict of interest indication, and if the paper submitted follows the journal’s policies, he makes a decision: (i) the paper is rejected, (ii) the paper needs major or minor corrections (the author is asked to make the corrections and resend it to the editor-in-chief who then makes a decision), or (iii) the paper is accepted.
-Copyright transfer form is sent to the author
-Paper is published.”
“Journal’s policies on Conflict of Interest, Human, and Animal Rights:
Conflict of Interest
All papers submitted to the editor-in-chief are sent to all members of the Board of Editors and Board of Director of the Asian Society of Pharmacognosy who in turn have the duty to alert the editor-in-chief if the paper is authored by their colleagues, friends, co-researchers, co-authors, family members, or students. If a conflict of interest exists the paper is rejected. Authors are asked to declare in the paper if they have any conflict of interest to declare
Human Rights:
The Asian Journal of Pharmacognosy does not publish papers involving experiments on human subjects that do not follow strictly the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008, which is available at http://www.healthscience.net/resources/declaration-of-helsinki/.
Animal Rights
The Asian Journal of Pharmacognosy does not publish papers involving experiments that do not follow the guidelines of the American Veterinary Medical Association (AVMA) for the Euthanasia of Animals (2020)( https://www.avma.org/sites/default/files/2020-01/2020-Euthanasia-Final-1-17-20.pdf ). Further, authors must provide detailed evidence on whether the institutional and national guide for the care and use of laboratory animals was followed. The materials and methods (experimental procedures) section must indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided. In general, the journal does not encourage the submission of papers involving in vivo works. Any deviation from the above will result in paper rejection.
Informed Consent:
The Asian Journal of Pharmacognosy rejects any paper that does not apply informed consent under research ethics, based on Declaration of Helsinki: Statement of Ethical Principles for Medical Research (https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/) and ICMJE's Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (http://www.icmje.org/icmje-recommendations.pdf). For publications involving patients for the Asian Journal of Pharmacognosy, patients have a right to privacy that should not be violated without informed consent. Identifying information, including names, initials, or hospital numbers, should not be published in written descriptions, photographs, or pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be published. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication. Patient consent should be written and archived either with the journal, the authors, or both, as dictated by local regulations or laws. Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance, and editors should so note, that such alterations do not distort scientific meaning. When informed consent has been obtained, it should be indicated in the published article.
